90Y-FAPi-46 is the therapeutic analogue of the PET imaging agent 68Ga-FAPi-46 from the FAPi family developed at the Cancer Research Center of Heidelberg, Germany. It is a radiotherapeutic agent based on a Fibroblast Activation Protein (FAP)-specific enzyme inhibitor (FAPi), to be found on almost all solid tumors. The first clinical dosimetry trial was performed at University Hospital Essen, Germany.
FAPis target cancer-associated fibroblasts (CAFs), yielding images with similar or better quality compared with 18F-FDG-PET/CT among patients with cancer and the 90Y-labeled analogue can find applications as therapeutics for these same patients. Besides cancer, FAPis may also be used for benign diseases such as fibroses, atherosclerosis, rheumatoid arthritis, sarcoidosis, etc.

Target/Mechanism: Fibroblasts


Radiation Type: beta electrons (β–)